ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Grand Pharmaceutical Group's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 2.83%.
As of today (2026-06-26), Grand Pharmaceutical Group's WACC % is 8.98%. Grand Pharmaceutical Group's ROC % is 6.07% (calculated using TTM income statement data).
Grand Pharmaceutical Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Grand Pharmaceutical Group (OTCPK:CGPHF) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Grand Pharmaceutical Group's WACC % is 8.98%. Grand Pharmaceutical Group's ROC % is 6.07% (calculated using TTM income statement data).
Grand Pharmaceutical Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (CGPHF) has a ROC % of 2.83% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's ROC % too high?
Grand Pharmaceutical Group's current ROC % is 2.83%. The Drug Manufacturers industry median ROC % is 4.44. Grand Pharmaceutical Group's value of 2.83% is 36.3% below this industry median. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's ROC % compare to ZTS?
Grand Pharmaceutical Group's ROC % of 2.83% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. Grand Pharmaceutical Group's value of 2.83% is 36.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current ROC % of 2.83% is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current ROC % is 2.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current ROC % of 2.83%. The current ROC % is 2.83% and 36.3% below the Drug Manufacturers industry median of 4.44. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current ROC % is 2.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 